In this issue of The Journal of Nuclear Medicine , Gabriel et al. ( [1][1] ) report their experience with 68Ga-labeled 1,4,7,10-tetraazacyclododecane- N,N′,N′′,N′′′ -tetraacetic acid-d-Phe1-Tyr3-octreotide (68Ga-DOTA-TOC) PET in a series of 84 patients with neuroendocrine tumors (NET).
No takes yet. Share an insight, caveat, or question.
Orazio Schillaci (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: